Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 4,457 shares of common stock and inducement restricted stock units, covering an aggregate of 3,343 shares of its common stock. The awards are subject to all terms and conditions and other provisions.

Business Wire • 19 hours ago

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away

New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP's 13F reportable assets under management.

The Motley Fool • Dec 3, 2025

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 3, 2025

Scholar Rock to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in the following investor conferences: Citi 2025 Global Healthcare Conference: Scholar Ro.

Business Wire • Nov 18, 2025

Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

Scholar Rock Holding Corporation ( SRRK ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Laura Ekas David Hallal - CEO & Chairman of the Board Akshay Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director R. Keith Woods Vikas Sinha - Chief Financial Officer Conference Call Participants Mani Foroohar - Leerink Partners LLC, Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Kripa Devarakonda Etzer Darout - Barclays Bank PLC, Research Division Marc Frahm - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Presentation Operator Good morning, ladies and gentlemen, and welcome to Scholar Rock's Third Quarter 2025 Conference Call.

Seeking Alpha • Nov 14, 2025

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments. “W.

Business Wire • Nov 14, 2025

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

Short interest data offers a look into investor sentiment and potential risk within the stock market and can help investors gauge how much skepticism or confidence the market has in a company's future.

Benzinga • Nov 13, 2025

3 Beaten-Down Stocks With Rebound Potential This Earnings Season

Earnings season often shines a spotlight on well-known mega-caps, but it can also bring opportunities for lesser-known companies to shine. Below are three stocks—each down significantly in 2025—that could stage a comeback if their upcoming earnings updates hit the right notes.

MarketBeat • Nov 12, 2025

Scholar Rock: De-Risked Biotech, Playing The Approval Catalyst (Buy Rating)

Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The recent stock correction was due to manufacturing site issues, not clinical setbacks; approval is expected by 2026, presenting a speculative buy opportunity.

Seeking Alpha • Nov 10, 2025

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Tuesday, Novembe.

Business Wire • Nov 4, 2025